Arena Pharmaceuticals Initiates Phase 2b Clinical Trial Of APD125 For The Treatment Of Insomnia

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that it initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candidate discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenance and quality.

More: continued here

Filed under: Clinical Trials on April 11th, 2008